Global pharmaceutical companies respond to Trump with historic investments: More than $450.000 billion for U.S. production.

 

The main companies in the sector have jointly announced investments exceeding 450.000 billion dollars in United States for the coming years, with the primary objective of increasing local drug production and avoiding the threat of tariffs of up to 100% on imported innovative drugs.

 

The offensive of Trump, which intensified pressure from the beginning of 2025 by warning about duty punitive measures if domestic manufacturing was not increased and consumer prices were not reduced, has catalyzed a strategic restructuring of the global supply chains.

 

Million-dollar Investments to Increase Internal Capacity

Pharmaceutical giants such as Pfizer, MSD, AstraZeneca, Johnson & Johnson and Roche They lead the investment commitment, seeking to align with trade policies that prioritize manufacturing on U.S. soil.

 

Pfizer stands out with an additional $70.000 billion investment in research and production in the country. This plan was implemented alongside an agreement with the administration that includes price reductions in the domestic market.

 

Johnson & Johnson will allocate $57.000 billion to build a state-of-the-art technology center in North Carolina.

 

Roche plans to invest $51.250 billion in new plants and expansions of existing facilities in several states.

 

AstraZeneca has committed $50.000 billion through 2030, focusing on the development of weight and metabolism management treatments.

 

Japanese pharmaceutical company Takeda announced a $30.000 billion five-year plan to strengthen its manufacturing and research and development (R&D) operations in the United States.

 

This influx of capital underscores a clear trend in the global industry: adapting to U.S. regulatory and trade demands to protect against potential economic sanctions and, simultaneously, responding to the demand for lower prices and greater access to medicines for citizens.

 

Pharmaceutical companies have framed these decisions as strategic moves that strengthen national productive capacity.